Cafelkibart clinical trials
Also written LM-108.
How each study uses cafelkibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cafelkibart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LM-108
- 4
Studies by the year they started
9 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2022 | 3 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 2
LaNova Medicines Limited (4) · Shanghai Pulmonary Hospital, Shanghai, China (2) · LaNova Australia Pty Limited (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Sintilimab (2) · Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 (1) · Anti-CTLA-4 Monoclonal Antibody IBI310 (1) · Penpulimab (1) · Oxaliplatin (1) · Capecitabine (1) · Tislelizumab (1)
Studies
Open first, then newest update. How each study uses cafelkibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction AdenocarcinomaRecruitingPhase 3LaNova Medicines LimitedNCT07362186Written as LM-108 in combination with Toripalimab
- Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort CRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06821503Written as LM-108 injection
- Clinical Studies for the Treatment of Advanced Solid TumorsRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06825494Written as LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine
- A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid TumoursNot yet recruitingPhase 2LaNova Medicines LimitedNCT06873854Written as LM-108
- Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical TrialNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06620822Written as LM-108+Sintilimab
- LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06479759Written as LM-108 antibody and sintilimab
- A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid TumorsActive, not recruitingPhase 1/2LaNova Medicines LimitedNCT05518045Written as LM-108
- Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid TumoursCompletedPhase 1/2LaNova Australia Pty LimitedNCT05199753Written as LM-108
- Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid TumoursTerminatedPhase 1/2LaNova Medicines LimitedNCT05255484Written as LM-108
Given beside what is tested · 1 — cafelkibart is usual care or a partner of the new treatment
Codes
What other systems call cafelkibart · ClinicalTrials.gg INT018604
- UNII (FDA) YN4XWR5BUJCAFELKIBARTOne source FDA
- NCI Thesaurus C186374CafelkibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | YN4XWR5BUJ | CAFELKIBART | One source FDA |
| NCI Thesaurus | C186374 | Cafelkibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.